Endo once more agrees to delay FDA litigation
September 24, 2018 at 12:11 PM EDT
The pharmaceutical company is challenging FDA policy on compounding, which could negatively impact an Endo blood pressure medicine.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|